title: Prevalence and correlates of human papillomavirus genotypes among patients with cervical cancer and cervical intraepithelial neoplasia 3 in Israel.
abstract: OBJECTIVE
  This study aimed to assess the prevalence of human papillomavirus (HPV) in Israeli patients with cervical cancer and cervical intraepithelial neoplasia 3 (CIN3), to describe the distribution of the virus genotypes among positive cases, to characterize patients positive to HPV and, in particular, patients positive to HPV-16 and/or -18, and to evaluate the possible contribution of implementing HPV vaccination in Israel.
  
  
  METHODS
  Samples from 84 patients with cervical cancer and 886 patients with CIN3, archived at the Maccabi Institute of Pathology, were screened for HPV. DNA extraction was performed using DNeasy Blood and Tissue Kit/QIAGEN. HPV detection and typing were performed by multiplex polymerase chain reaction with primers E6/E7, using the f-HPV/Genomed kit.
  
  
  RESULTS
  Of the samples from 84 patients with cervical cancer, 89.3% were positive for HPV. Among these positive samples, HPV-16 was found in 70.7% and HPV-18 was found in 9.3%. Of the samples from 886 patients with CIN3, 85.0% were positive for HPV. Among these positive samples, HPV-16 was found in 73.8% and HPV-18 was found in 1.1%. In the patients with CIN3, the prevalence of HPV genotypes 16 and/or 18 was higher among young women and decreased across age groups. In addition, age, being born in Israel, being born in Europe, and being born in the former Soviet Union were correlated with a low risk of being infected with genotypes 16 and/or 18.
  
  
  CONCLUSIONS
  The prevalence of HPV-16 and -18 in patients with cervical cancer and CIN3 in Israel is high. It is expected that the implementation of routine vaccination against these types of HPV will significantly reduce the burden of these diseases in Israel.
authors.affiliation: 1Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2Israel Center for Disease Control, Ministry of Health, Sheba Medical Center, Ramat Gan, Israel; 3Institute of Pathology, Central Lab, Maccabi Healthcare Services, Rehovot, Israel; 4Women Health Center, Maccabi Healthcare Services, Tel Aviv, Israel; 5Stanley Steyer Institute for Epidemiology and Research, Tel Aviv University, Tel Aviv, Israel; and 6School of Public Health, University of Haifa, Haifa, Israel.
authors.forename: Ravit
authors.initials: R
authors.lastname: Bassal
authors.forename: Lia Supino
authors.initials: LS
authors.lastname: Rosin
authors.forename: Michael
authors.initials: M
authors.lastname: Schvimer
authors.forename: Eduardo
authors.initials: E
authors.lastname: Schejter
authors.forename: Bella
authors.initials: B
authors.lastname: Ozeryansky
authors.forename: Svetlana
authors.initials: S
authors.lastname: Kulik
authors.forename: Rachel
authors.initials: R
authors.lastname: Bachar
authors.forename: Hagit
authors.initials: H
authors.lastname: Shapira
authors.forename: Judith
authors.initials: J
authors.lastname: Sandbank
authors.forename: Daniel
authors.initials: D
authors.lastname: Cohen
authors.forename: Lital
authors.initials: L
authors.lastname: Keinan-Boker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D006801:Humans; D007557:Israel / Q000453:epidemiology; D008875:Middle Aged; D060885:Multiplex Polymerase Chain Reaction; D009856:Oncogene Proteins, Viral / Q000235:genetics; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000821:virology*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000821:virology*
chemical_list: D009856:Oncogene Proteins, Viral